Hainan Hailing Chemipharma Co., Ltd. is the primary pharmaceutical organization associated with Steven Li’s current professional role. This page creates a stable public reference for partners and search systems without replacing the company’s official corporate, product, regulatory or pharmacovigilance channels.

Company at a glance

Legal name
Hainan Hailing Chemipharma Co., Ltd. · 海南海灵化学制药有限公司
Founded
2004
Public business scope
Pharmaceutical research and development, manufacturing and commercialization.
Public address
No. 281 Nanhai Avenue, Haikou, Hainan, China 570311.
R&D history
The official website records that the R&D center was established in 2004.
Cooperation history
The official website records exploration of diversified R&D and industry collaboration since 2007.

Confirmed dosage-form platforms

Sterile injectables

Sterile lyophilized powder injections, sterile powder injections and terminally sterilized small-volume injections.

Oral solid dosage forms

Tablets and capsules.

Topical dosage forms

Creams and ointments.

These are publicly confirmed platform categories. They do not establish the availability, registration, capacity, packaging, analytical scope or market eligibility of any named product. Those questions require a current project review.

Public product fields

The company’s official public product navigation covers dermatology, anti-infectives, gastrointestinal, cardiovascular, diabetes and nervous-system medicines. A therapeutic field is not evidence that every product in that field is currently approved, marketed, available for export or open for contract manufacturing.

Quality and regulatory wording

U.S. FDA inspection experience

Hainan Hailing underwent an on-site U.S. FDA inspection in July 2021. In its 8 October 2021 90-day decisional letter, the FDA classified the inspection as Voluntary Action Indicated (VAI) and confirmed that the inspection was closed. This describes a dated inspection outcome; it is not an FDA certification, facility approval or endorsement.

China GMP compliance

Hainan Hailing operates under applicable Chinese pharmaceutical GMP requirements and is subject to ongoing regulatory oversight. This website does not describe the company as holding a current “China GMP certificate.”

Cooperation pathways

Initial discussions may cover CMO, CDMO, technology transfer, product and registration cooperation, and domestic or international pharmaceutical business development. Every pathway remains subject to technical fit, current capacity, applicable authorization, quality and regulatory review, and an agreed written scope.

Sterile injectable CMO/CDMOView platform fit and assessment stages → ASEAN partnershipsView the country-by-country cooperation model → Pharmaceutical insightsRead source-backed long-form analysis →

What this page does not claim

  • No product count is presented without a current, dated and status-qualified schedule.
  • No production-site or line count is used without current operational verification.
  • No product is represented as approved or available in a target market unless confirmed for that market.
  • No inspection history is represented as a permanent certification or product-specific readiness.

Public sources and review basis

  1. Hainan Hailing official company profile
  2. Hainan Hailing public product fields
  3. Hainan Hailing R&D center page
  4. Hainan Hailing technical cooperation page
  5. U.S. FDA 90-Day Decisional Letter dated 8 October 2021, FEI 3006643956; reviewed copy retained in the website evidence record.

This page supports general institution-to-institution business discussion. It is not medical, legal or regulatory advice and does not replace official corporate channels. Project requirements must be confirmed against current records and applicable requirements.